johnson-and-johnson
(8)Aahuti Patel and the quiet arithmetic behind a $94 billion company
Aahuti Patel works where forecasts become choices: inside the North American finance operation of Johnson & Johnson. Her sparse public profile reveals a career built around scale, judgment and the unglamorous discipline of making numbers useful.
Gail Horwood
From hand-built recipe pages to highly regulated brand storytelling, Gail Horwood has spent three decades asking the same useful question: what does the audience need next?
Serge Messerlian
Serge Messerlian is the Chairman and CEO of Creyon Bio, a San Diego biotech using AI to design oligonucleotide medicines. A life-science operator with more than 25 years across oncology, hematology, immunology and rare disease, he has led Teon Therapeutics as CEO, run Janssen Oncology as President at Johnson & Johnson, and held senior roles at Actelion, Baxalta and Baxter International. He joined Creyon first as an investor and board member through DCVC Bio, then stepped in as Executive Chairman and Acting CEO in fall 2024 and took the full CEO title in April 2025 as the company prepares to enter the clinic in 2026.
Sebby Borriello
Sebby Borriello is a pharmaceutical and medical-device commercialization veteran with 30-plus years of go-to-market leadership. After 25 years at Johnson & Johnson across wound management, biosurgery and aesthetics, he helped turn South Korea's SK Life Science from an R&D-only shop into a fully integrated US pharma company, leading the 2020 launch of its first FDA-approved drug, the epilepsy treatment XCOPRI. He later advised and joined Carmell Therapeutics as Chief Business Officer, and today serves as Executive Vice President and Chief Commercial Officer at MIDAS Healthcare Solutions, a New York startup tackling medication diversion and drug-waste accountability through its MidasVIEW platform and Anytime Witness video-verification technology.
Charles R. Bridges
Charles R. Bridges, M.D., Sc.D., is Executive Vice President and Chief Scientific Officer at CorVista Health, where he leads the science behind a machine-learning cardiac diagnostic platform. A cardiac surgeon turned engineer-executive, he holds an A.B. in applied physics from Harvard, an M.D. from Harvard Medical School (which he entered at 18), and both an M.S. in electrical engineering and a D.Sc. in chemical engineering from MIT. He was the first African American full professor of surgery at the University of Pennsylvania, served as a technology chief at Johnson & Johnson's Janssen, and in 2022 was elected to the U.S. National Academy of Engineering. His record spans 175 peer-reviewed publications, 15 patents, and more than $10 million in continuous NIH funding.
Frederic Dijols
Frederic Dijols is the co-founder and CEO of Mixlab, a veterinary-exclusive pet pharmacy that compounds custom medications and delivers them fast and free to pet parents and the vets who prescribe them. A French-trained engineer with degrees from Ecole Polytechnique, Stanford, and Harvard Business School, he traded a healthcare-banking seat at J.P. Morgan for a pharmacy floor after a miserable experience getting meds for his aging pug, Bob. Since 2017 he has raised roughly $46.5M and built Mixlab into a multi-state operation pairing pharmacist-grade compounding with consumer-grade delight.
John Balian
John D. Balian, MD is a physician-turned-executive who co-founded ClinChoice, one of the world's larger full-service contract research organizations, and serves as its CEO, International. He spent years inside the FDA, then ran drug safety and regulatory operations at Pfizer, Bristol-Myers Squibb and Johnson & Johnson before building a global CRO spanning the US, Europe and Southeast Asia. He is also a published novelist whose debut, Gray Wolves and White Doves, draws on his Armenian heritage and the Armenian Genocide.
Souvik Paul
Souvik Paul is the CEO and Founder of Aurie, a medtech company that built the first FDA De Novo-cleared reusable intermittent catheter system. A Harvard-educated designer and former J&J strategist, Paul was driven to start Aurie after witnessing a family member's struggle with catheter-associated infections following a spinal cord injury. His Oakland-based startup has raised $14.24M and is pioneering a no-touch, automatically disinfecting catheter system designed to transform care for the 600,000 Americans who rely on intermittent catheters.